Sreyan et al. designed E. coli strains containing synchronous lysis circuits to colonize tumors with CD47-releasing nano-antibody antagonists, increasing the activation of tumor-infiltrating T cells and inducing persistent and systemic anti-tumor immunity (Chowdhury et al., 2019). This evidence concerns the gene CD47 and neoplasm.